ASY 77A
Alternative Names: ASY-77ALatest Information Update: 02 Jun 2021
Price :
$50 *
At a glance
- Originator University of Texas M. D. Anderson Cancer Center
- Developer Asylia Therapeutics
- Class Antibodies; Antineoplastics; Immunotherapies
- Mechanism of Action Dendritic cell stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Cancer